Tonghua Jinma: Plans to establish a wholly-owned subsidiary called Guilin Jinma Innovation Investment with a proposed investment of 70 million yuan.

The announcement by Tonghua Jinma stated that on November 6, 2025, the company held the eighth interim meeting of the eleventh board of directors of 2025 to review and approve the proposal to invest in the establishment of a wholly-owned subsidiary. The company plans to establish Guilin Jinma Innovation Investment Co., Ltd. with 70 million yuan in self-owned or self-raised funds, with Wang Huan as the legal representative, and the company holding 100% of the shares. This investment is within the approval authority of the board of directors, does not constitute related party transactions or major asset restructuring. The purpose is to carry out innovative drug industry merger and acquisition layout around the transformation strategy, although it may be affected by industry policies and other factors, it is beneficial for the company to optimize its industrial layout.